Anthem Says Will Not Cover Sarepta’s Approved Duchenne Drug

Reuters, October 7, 2016. To keep health insurance affordable, companies need to ensure that they are paying for safe and effective treatments, said Diana Zuckerman, president of non-profit organization National Center for Health Research. “When FDA fails to ensure those standards, then ‘FDA approval’ is no longer a gold standard that insurance companies can rely on,” she said.

Read More »

Does the FDA Have a High Enough Standard for Drug Approvals?

STAT News, September 28, 2016. Is the Food and Drug Administration’s approval process broken? At a HUBweek panel hosted by STAT, experts explored that question in light of the FDA’s decision last week to approve a controversial drug for Duchenne muscular dystrophy, a rare disease.

Read More »

Furor Over Drug Prices Puts Patient Advocacy Groups in Bind

The New York Times, September 27, 2016. Public anger over the cost of medical products has burned hot for a year, coursing through social media, popping up on the presidential campaign, and erupting in a series of congressional hearings, including one last week over the rising price of the allergy treatment EpiPen.

Read More »